Settlement with Dr. Reddy's Laboratories

RNS Number : 1434Q

Indivior PLC

24 June 2022

 

Indivior Reaches Settlement with Dr. Reddy's Laboratories in Patent Infringement Case

Slough, UK and Richmond, VA, June 24, 2022 - Indivior PLC, (LON: INDV) announced that together with Aquestive Therapeutics, Inc. it entered into a settlement agreement with Dr. Reddy's Laboratories Ltd. (DRL) and its subsidiaries resolving patent litigation relating to DRL's generic buprenorphine and naloxone sublingual film, a therapeutic equivalent generic version of SUBOXONE® (buprenorphine and naloxone) sublingual film.  The confidential settlement resolves all claims between the parties and the amount paid by Indivior to DRL pursuant to the settlement is consistent with its previously disclosed reserve amount. 

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting   www.linkedin.com/company/indivior .

For Further Information

Jason Thompson	VP, Investor Relations Indivior PLC	[phone] [e-mail]
Tim Owens	Director, Investor Relations Indivior PLC	[phone] [e-mail]

-ends-

 

END

 

 

UPDBKQBQKBKDNAB